Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced bile duct cancer: liver transplant after targeted radiation

NCT ID NCT06910722

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a liver transplant after a combination of targeted internal radiation (SIRT with Yttrium-90) and chemotherapy can improve 3-year survival in people with locally advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be surgically removed. The trial plans to enroll 36 participants in France. The main goal is to see if this strategy helps patients live longer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Yttrium-90 (radioactive beads) and chemotherapy
What this could lead to
If successful, this could offer a potential treatment path for people with advanced bile duct cancer that cannot be surgically removed, possibly improving long-term survival.
What could go wrong
This is a small, early-phase study with only 36 participants. The treatment is complex and carries risks from radiation, chemotherapy, and transplant surgery. It may not work for everyone or may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Oct 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 18 to 65 * With histologically documented intrahepatic cholangiocarcinoma (primary diagnosis): * Uni or pauci nodular (≤ 5 lesions (all lesions are counted, even those less than 1 cm)) * Without extrahepatic or lymph node involvement * Technically unresectable R0 according to an expert panel * Tumor target \> 2 cm * WHO 0-1 * free and informed consent signed * highly effective contraception for men and women of childbearing age during study participation up to 2 years post TH Exclusion Criteria: * Extrahepatic, vesicular or perihilar cholangiocarcinoma * Tumor infiltration of more than 50% of the liver * Mixed cholangiocarcinoma, hepatocellular carcinoma, fibrolamellar carcinoma * Previous treatment for CCI * Cirrhosis ≥ Child B7 * Chronic alcoholism * Uncontrolled chronic active infections (patients with HBV, HCV or HDV infections may be included if infections are controlled) * Stage III A, IIIB, IV and V chronic renal failure (glomerular filtration rate 59 ml/min) * Contraindications to liver transplant * Severe untreatable conditions * Recent history (less than 5 years) of cancer * severe comorbidities * Psychiatric or psychological disorders * Pregnant or breast-feeding women * Patient under guardianship * Not affiliated to a Health care system * Participating in another interventional study or within the exclusion period of a previous study involving the human body

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intrahepatic cholangiocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intrahepatic cholangiocarcinoma Locally advanced intrahepatic cholangiocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beaujon

    RECRUITING

    Clichy-sous-Bois, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.